Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

Name: Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
Published: 2013
License: Public Domain

Merck Sharp & Dohme LLC · 2013

ClinicalTrials.gov · Datasets · License: Public Domain · 2013

Open Source ↗

non small cell lung cancer (nsclc), programmed cell death-1 (pd1, pd-1), programmed death-ligand 1 (pdl1, pd-l1), interventional, phase2, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

Related documents